UNSPSC 51333414: Ziprasidone hydrochloride hydrate

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, hydrochloride, hydrate (1:1:1), but more generally known as ziprasidone hydrochloride hydrate, which bears US NIH Compound Identifier 60853.

European Medicines Agency schedules ziprasidone hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. Most nations, for tariff purposes, schedule ziprasidone hydrochloride hydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.CL.

UNSPSC 51333414 Ziprasidone hydrochloride hydrate is a Commodity code that does not reflect the state and local procurement activity recently tagged under it. The sole recent opportunity in the dataset—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023—solicits Naloxone and Safe Drug Deactivation Systems, products entirely unrelated to ziprasidone, an atypical antipsychotic pharmaceutical. This mislabeling suggests either a coding error in the source or a metadata inconsistency between the UNSPSC taxonomy assignment and the actual procurement scope. The code shows little to no relevant recent activity aligned with its nominal pharmaceutical commodity.

Without additional opportunities properly coded to this Commodity, no reliable characterization of issuing-body mix, geographic concentration, or actual purchasing patterns under UNSPSC 51333414 can be drawn from the available data. State and local procurement of ziprasidone hydrochloride hydrate may occur through pharmacy benefit managers, state Medicaid programs, or health department acquisitions, but the current dataset does not surface representative examples. Practitioners evaluating this code should verify its accuracy in their own sourcing systems and consider whether opportunities for psychiatric medications are being filed under different UNSPSC codes at their target agencies.